BIT's 17th Annual Congress of International Drug Discovery Science and Technology (IDDST-2019)

BIT's 17th Annual Congress of International Drug Discovery Science and Technology (IDDST-2019)

Scientific Program

Scientific Program
Stream 1	Stream 2	Stream 3	Stream 4	Stream 5

Stream 2: Drug Discovery S & T

Stream 2-1: Frontiers in Drug Discovery Science
Stream 2-2: Innovative Drug Discovery Technologies

Stream 2-1: Frontiers in Drug Discovery Science

Session 211: Recent Advances in Pharmacology and Toxicology
Day 1: Afternoon, Thursday, July 25, 2019 Place: Room F, 1st Floor
Chair: Dr. Meredith Rocca, Senior Scientific Director, Nonclinical Safety, Janssen Research and Development, USA
Co-Chair: Dr. Kim Li, Senior Manager, EHSS Product Stewardship, Amgen Inc., USA
Time	Speeches and Speakers
13:30-13:35	Chair’s Introduction
13:35-13:55	Keynote Speech Title: The Green Tea Amino Acid Theanine Promotes Neurogenesis for Brain Health Dr. Yukio Yoneda, Invited Professor, Osaka University, Japan
13:55-14:15	Title: Holistic QbD Approach for Impurities Control and Management: Implications for the Development of Biotechnology Products Dr. Kim Li, Senior Manager, EHSS Product Stewardship, Amgen Inc., USA
14:15-14:35	Title: Applying a Weight of Evidence Approach to the Evaluation of Developmental Toxicity of Biopharmaceuticals Dr. Meredith Rocca, Senior Scientific Director, Nonclinical Safety, Janssen Research and Development, USA
14:35-14:55	Title: Na^+/H⁺Exchangers Perform Isotopic Fractionation of Transported Cations Dr. Laurent Counillon, Professor, University of Nice-Sophia Antipolis, France
14:55-15:15	Title: Hydromorphone Induced Neurotoxicity in Palliative Care Ms. Olfat Zekry, Pharmacology Unit Coordinator, Pain Education Unit, Pain Management Research Institute, Sydney Medical School, The University of Sydney, Australia
15:15-15:30	Coffee Break
15:30-15:50	Title: Tuning CD3 Bispecific Antibodies for Safety and Efficacy Dr. Jacintha Shenton, Scientific Director, Biologics Toxicology, Janssen R&D, USA
15:50-16:10	Title: Role of 20-HETE in Stroke and Dementia Dr. Fan Fan, Assistant Professor, Department of Pharmacology & Toxicology, The University of Mississippi Medical Center, USA
16:10-16:30	Title: Inhibition of Breast Cancer Bone Metastasis and Pancreatic and Colon Cancer by Synthetic Curcumin Analogs Dr. Mamoru Shoji, Associate Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, USA
16:30-16:50	Title: All-trans Retinoic Acid Reverses Epithelial-mesenchymal Transition in Paclitaxel-resistant Cells by Inhibiting Nuclear Factor Kappa B and Upregulating Gap Junctions Dr. Yijia Wang, Associate Professor, Tianjin Union Medical Center, China
16:50-17:10	Panel Discussion

Session 212: Pharmacogenetics, Pharmacogenomics and Precision Medicine
Day 2: Morning, Friday, July 26, 2019 Place: Room F, 1st Floor
Chair: Dr. Wei Xu, Associate Professor, Dalla Lana School of Public Health, University of Toronto, Canada
Co-Chair: Dr. Natalie Pankova, Chief Operating Officer, Metadvice Ltd, UK
Time	Speeches and Speakers
08:30-08:35	Chair’s Introduction
08:35-08:55	Title: Pharmacogenomic Analyses of Quality of Life and Overall Survival on Colorectal Cancer Patients Dr. Wei Xu, Associate Professor, Dalla Lana School of Public Health, University of Toronto, Canada
08:55-09:15	Title: Impact of the Arg 16 Allele of the B2AR Gene on the Effect of Withdrawal of LABA in Patients with Moderate to Severe Asthma Dr. Marjorie Slankard, Professor, Department of Medicine, Columbia University, USA
09:15-09:35	Title: Systems Genetics for Precision Medicine Dr. Kristel Van Steen, Professor, University of Liege/KU Leuven, Belgium
09:35-09:55	Title: Blockchain Can Catalyze Improvements in Health Data Sharing Systems and Processes and Accelerate Precision Medicine Dr. Natalie Pankova, Chief Operating Officer, Metadvice Ltd, UK
09:55-10:15	Title: The Genetics-epigenetics Chronologies and Hierarchies in Personalized Medicine of Colon Cancer Dr. Manuel Perucho, Director, Program Predictive & Personalized Medicine of Cancer (PMPPC) of the Research Institute Germans Trias I Pujol (IGTP), Spain
10:15-10:30	Coffee Break
10:30-10:50	Title: The State of Precision Medicine – Market, Regulatory, Legal and IP Considerations Dr. Qin Shi, Managing Principal, EdgeTech Law LLP, USA
10:50-11:10	Title: Robust Reproducible LC/MS Based Metabolomic Profiling of Large Cohort Human Studies Using Validated High Throughput Targeted and Discovery Assays Dr. Robert S. Plumb, Professor, Waters Corporation, USA
11:10-11:30	Title: Venlafaxine and MDMA: Similar Transcriptional Effects? Dr. Peter Petschner, Assistant Professor, Semmelweis University, Hungary
11:30-11:50	Title: Identification of Multi-omic Markers of an Allergic Reaction Using Novel LC-MS Methodologies Dr. Lee Gethings, Senior Manager, Waters Corporation, UK
11:50-12:10	Panel Discussion

Session 213: Drug Metabolism and Interactions
Day 2: Morning, Friday, July 26, 2019 Place: Room G, 1st Floor
Chair: Dr. Hua Yang, VP, Agios Pharmaceuticals, Inc., USA
Co-Chair: Dr. Tycho Heimbach, Director, PK Sciences, PBPK and Biopharmaceutics, Novartis Institutes for Biomedical Research, USA
Time	Speeches and Speakers
08:30-08:35	Chair’s Introduction
08:35-08:55	Keynote Speech Title: Regulation of the ABCG2 Multidrug Transporter and Its Potential Role in Clinical Drug Effects Dr. Balázs Sarkadi, Professor, Research Centre for Natural Sciences, Institute of Enzymology, Hungarian Academy of Sciences, Hungary
08:55-09:15	Title: PBPK Modeling in Drug Discovery and Development Dr. Tycho Heimbach, Director, PK Sciences, PBPK and Biopharmaceutics, Novartis Institutes for Biomedical Research, USA
09:15-09:35	Title: Phase 1 Single and Multiple-ascending-dose Randomized Studies of the Safety, Pharmacokinetics, and Pharmacodynamics of Mitapivat (AG-348), A First-in-class Allosteric Activator of Pyruvate Kinase R, In Healthy Volunteers Dr. Hua Yang, VP, Agios Pharmaceuticals, Inc., USA
09:35-09:55	Title: A Long-term Culture System Based on a Collagen Vitrigel Membrane Chamber that Activate Cytochrome P450 and Liver-specific Functions of Hepatocytes Dr. Ryuji Watari, Drug Metabolism and Pharmacokinetics Tsukuba, Global Drug Metabolism and Pharmacokinetics, Biopharmaceutical Assessments Core Function Unit, Medicine Development Center, Eisai Co., Ltd., Japan
09:55-10:15	Title: Protein Abundance of Clinically Relevant Drug Transporters in the Human Liver Pathology Dr. Marek Drozdzik, Head, Department of Pharmacology, Pomeranian Medical University, Poland
10:15-10:30	Coffee Break
10:30-10:50	Keynote Speech Title: FDA’s Expedited Testing and Approval: How to Fast Track the Drug Approval Dr. Aruna Dontabhaktuni, President & CEO, PharmaPro Consulting, USA
10:50-11:10	Title: Analysis of Mercury(II) Recognition Ability and Study on Synthesis Condition of p-tert-butylcalix[4]thiacrown-5 Aiming at Selective Removal of Mercury(II) Species in Human Body Dr. Tatsuya Takimoto, Assistant Professor, Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Japan
11:10-11:30	Title: A Computational Study on the Molecular Recognition and Plasticity of Cytochrome P450 3A4 Dr. Maria Kontoyianni, Professor, Southern Illinois University Edwardsville, USA
11:30-11:50	Title: Food-drug Interactions Involving Multiple Mechanisms: A Case Study with Effect of Capsaicin on the Pharmacokinetics of Irinotecan and Its Main Metabolites in Rat Dr. Xuejia Zhai, Associate Professor of Pharmacy, Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, China
11:50-12:10	Panel Discussion

Session 214: Oncology and Drug Discovery
Day 3: Morning, Saturday, July 27, 2019 Place: Room F, 1st Floor
Chair: Dr. Hiroshi Maruta, Professor, PAK Research Center, Australia
Co-Chair: Dr. Xiaohua Jiang, Professor, The Chinese University of Hong Kong, Hong Kong, China
Time	Speeches and Speakers
08:30-08:35	Chair’s Introduction
08:35-09:00	Title: 15K and MART-10: Two Potent PAK1-blockers from an Old Pain-killer (Ketorolac) and Vitamin D3 that Boost over 500 Times Their Anti-cancer Property Dr. Hiroshi Maruta, Professor, PAK Research Center, Australia
09:00-09:25	Title: The Activity of Fibrinogen-like Protein 2 (Fgl2) is Raised in Platelets of Patients with Malignancies Dr. Esther Rabizadeh, Director, Hematology Laboratories, Rabin Medical Center, Campus Beilinson; Head of Team Hemato-Oncology Research, Tel-Aviv University, Israel
09:25-09:50	Title: Signals that Regulate Inflammation and Systemic Metabolism in Notch/Pten-driven Tumors Dr. Maria Dominguez, Professor, Institute of Neuroscience National Spanish Research Council (CSIC) and Miguel Hernandez University, Spain
09:50-10:15	Title: R-spondin 2 Enhances Canonical Wnt Signaling to Maintain the Stemness of Glioblastoma Cells Dr. Xiaohua Jiang, Professor, The Chinese University of Hong Kong, Hong Kong, China
10:15-10:30	Coffee Break
10:30-10:55	Title: Dynamic Changes and Aberrant Differential Expression of EZH1 and EZH2 in Polycomb Repressive Complex 2 among B- and T/NK-cell Neoplasms Dr. Takashi Oka, Lecturer, Okayama University, Japan
10:55-11:20	Title: Nuclear Receptor CAR Suppresses GADD45B-p38 MAPK Signaling to Promote Phenobarbital-induced Proliferation in Mouse Liver Dr. Takeshi Hori, National Institute of Environmental Health Sciences (NIEHS)/National Institutes of Health (NIH), USA
11:20-11:45	Title: Drug Target Discovery for Cancer with MR4 Cancer, A Web Server Prioritizing Key Regulators for Cancer Dr. Jiangwen Zhang, Associate Professor, University of Hong Kong, Hong Kong, China
11:45-12:10	Panel Discussion

Session 215: Neurobiology and Drug Discovery
Day 3: Afternoon, Saturday, July 27, 2019 Place: Room F, 1st Floor
Chair: Dr. Anat Elmann, Research Scientist, Volcani Center, Agricultural Research Organization, Israel
Co-Chair: Dr. Emer Leahy, President & CEO, Psychogenics, Inc., USA
Time	Speeches and Speakers
13:30-13:35	Chair’s Introduction
13:35-14:00	Title: AI-driven Phenotypic Drug Discovery Delivers First-in-class, Clinically Effective Neuropsychiatric Treatments Dr. Emer Leahy, President & CEO, Psychogenics, Inc., USA
14:00-14:25	Title: Genetic Discovery on APBB2 Reveals a Pathway Connecting Neurodegeneration in Heroin Dependence Dr. Yu-Li Liu, Investigator, Center for Neuropsychiatric Research, National Health Research Institutes, Taiwan
14:25-14:50	Title: Genomics of Depression: Novel Mechanisms and Potentials for New Therapeutic Approaches Dr. Gyorgy Bagdy, Professor, Semmelweis University, Hungary
14:50-15:15	Title: Lessons from Comorbidities of Depression Dr. Gabriella Juhasz, Associate Professor, Semmelweis University, Hungary
15:15-15:30	Coffee Break
15:30-15:55	Title: Harnessing Phytochemicals to Protect Neuronal Cells Dr. Anat Elmann, Research Scientist, Volcani Center, Agricultural Research Organization, Israel
15:55-16:20	Title: Enolase1 Alleviates Cerebral Ischemia-induced Neuronal Injuryvia Its Enzymatic Product Phosphoenolpyruvate Dr. Haijun Tu, Professor & Assistant Dean, College of Biology, Hunan University, China
16:20-16:45	Title: The Effect of Selenium on the Proteome of Alzheimer's Disease Mice – Providing New Insights into the Mechanisms of Se Ameliorates Neuropathology and Cognitive Deficits of AD Mice Dr. Liming Shen, Associate Professor, College of Life Sciences and Oceanography, Shenzhen University, China
16:45-17:10	Panel Discussion

© 2003-2019 All rights reserved by BITeomics
Contact Us: Tel: 0086-411-84799609, Fax: 0086-411-84796897